

1 **Target temperature management and post-extracorporeal cardiopulmonary**
2 **resuscitation outcome: A post hoc analysis of the SAVE-J II Study**

3

4 **Short title:** Post-ECPR target temperature management

5

6 Jun Kanda M.D., Ph.D. ^{1,2}

7 Shinji Nakahara M.D., Ph.D. ¹

8 Akihiko Inoue M.D., Ph.D. ^{2,3}

9 Toru Hifumi M.D., Ph.D. ^{2,4}

10 Tomoya Okazaki M.D., Ph.D. ^{2,5}

11 Migaku Kikuchi M.D., Ph.D. ^{2,6}

12 Shoji Yokobori M.D., Ph.D. ^{2,7}

13 Yasufumi Miyake M.D., Ph.D. ¹

14 Naoto Morimura M.D., Ph.D. ¹

15 Tetsuya Sakamoto M.D., Ph.D. ^{1,2}

16 Yasuhiro Kuroda M.D., Ph.D. ^{2,5}

17

18 ¹ Department of Emergency Medicine, Teikyo University school of Medicine, Tokyo, Japan.

19 ² SAVE-J II study group

20 ³ Department of Emergency and Critical Care Medicine, Hyogo Emergency Medical Center,
21 Kobe, Japan.

22 ⁴ Department of Emergency and Critical Care Medicine, St. Luke's International Hospital,
23 Tokyo, Japan.

24 ⁵ Department of Emergency, Disaster and Critical Care Medicine, Kagawa University
25 Hospital, Kagawa, Japan.

26 ⁶ Emergency and Critical Care Center, Dokkyo Medical University, Tochigi, Japan

27 ⁷ Department of Emergency and Critical Care Medicine, Nippon Medical School, Tokyo,

28 Japan

29

30 **Corresponding author:** Jun Kanda

31 Department of Emergency Medicine, Teikyo University school of Medicine

32 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8606, Japan

33 Telephone number: +81-3-3964-1211

34 Fax number: +81-3-3964-0854

35 Email: jkanda-cib@umin.ac.jp

36

37 **Word Count:** 6051

38

39

40

41

42

43

44

45

46

47

48

49

50

51 **Abstract**

52 **Background:** The conflicting results of previous analyses about hypothermia management
53 in patients with out-of-hospital cardiopulmonary arrest have hindered the establishment of a
54 uniform standard temperature setting for temperature control. This study investigated and
55 compared the clinical outcomes of hypothermic (target temperature: 32–34°C) and
56 normothermic (35–36°C) management of out-of-hospital cardiac arrest (OHCA) patients,
57 treated with extracorporeal cardiopulmonary resuscitation (ECPR).

58 **Methods:** This secondary analysis of the SAVE-J II study, a retrospective, multicenter,
59 registry study involving 36 participating institutions in Japan, was undertaken, and ECPR
60 patients with a suspected cardiac etiology were included in this cohort. The primary outcome
61 was survival at hospital discharge. Favorable neurological outcomes (5-point Glasgow-
62 Pittsburgh Cerebral Performance Categories 1–2) constituted the secondary outcome.
63 Multivariable logistic analysis, which was adjusted for potential confounders, was performed
64 for the primary and secondary outcomes.

65 **Results:** Of the 949 participants of this study, 57% underwent hypothermic management. A
66 total favorable neurological outcome at hospital discharge was identified in 164 patients
67 (17%), and the survival rate was 35%. In multivariable analysis, with the primary and
68 secondary endpoints as each dependent variable, and gender, age, witness, bystander CPR,
69 electrocardiogram, low flow time, and causative disease as categorical covariates,
70 hypothermic management compared to normothermic management in OHCA patients treated
71 with ECPR, was not significantly associated with a favorable neurological outcome (adjusted
72 odds ratio (aOR) : 1.22; 95% CI: 0.85–1.74), but was associated with survival (aOR: 1.74;
73 95% CI: 1.31–2.32).

74 **Conclusions:** Compared to normothermic management, hypothermic management of OHCA
75 patients treated with ECPR was not significantly associated with a favorable neurological
76 outcome, but was associated with survival at hospital discharge.

77

78 **Clinical Perspective**

79 1) What is new?

- 80 • This study showed that hypothermia (32–34°C) management of body temperature
81 after ECPR induction resulted in better survival.
- 82 • In the secondary analysis, the prognosis of hypothermia management in
83 cardiogenicity other than acute coronary syndrome (arrhythmia, myopathy,
84 myocarditis, and other cardiac causes) was particularly good.

85 2) What are the clinical implications?

- 86 • Hypothermic management after cardiopulmonary arrest should be implemented if
87 ECMO ensures stable circulatory dynamics.

88

89 **Non-standard Abbreviations and Acronyms**

90 ACS: acute coronary syndrome, CPC: cerebral performance categories, cOR: crude odds
91 ratio, aOR: adjusted odds ratio, CPR: cardiopulmonary resuscitation, ECG:
92 electrocardiogram, ECMO: extracorporeal cardiopulmonary resuscitation, OHCA: out-of-
93 hospital cardiac arrest, PEA: pulseless electrical activity, VF: ventricular fibrillation, VT:
94 ventricular tachycardia.

95 **Background**

96 Extracorporeal cardiopulmonary resuscitation (ECPR), which combines extracorporeal
97 membrane oxygenation (ECMO) with conventional cardiopulmonary resuscitation (CPR), is
98 a more aggressive cardiopulmonary resuscitation technique in patients with cardiopulmonary
99 arrest, that facilitates early resumption of cerebral blood flow.¹ Sakamoto et al. reported that
100 in out-of-hospital cardiac arrest (OHCA) patients with ventricular fibrillation (VF) /
101 ventricular tachycardia (VT) on the initial ECG, a treatment bundle including ECPR,
102 therapeutic hypothermia, and intra-aortic balloon pumping (IABP) was associated with
103 improved neurological outcome at 1 and 6 months after OHCA compared to that by
104 conventional CPR; thus, ECPR may improve neurological outcomes.² However, the selection
105 of patients for ECMO and its management have not been adequately studied, and each
106 institution currently operates following institutional criteria.³

107 In contrast, in 2002, the Hypothermia After Cardiac Arrest Study Group and Bernard
108 SA reported that hypothermia management at 32–34°C and 33°C, respectively, resulted in
109 better outcomes than did conventional temperature management, in patients with out-of-
110 hospital cardiopulmonary arrest with prolonged loss of consciousness after resumption of
111 heartbeat; these studies constituted the basis for various guidelines worldwide.⁴⁻⁶ However,
112 additional studies on hypothermia management, such as the Targeted Temperature
113 Management Trial (TTM)-1 Study in 2013 and the TTM-2 Study in 2021, found no
114 difference in outcome between normothermic management, which avoids hyperthermia and
115 maintains a normal temperature, and hypothermic management, which targets temperatures
116 of 32–34°C, and recommended that there is no need to use hypothermic management.^{7,8}
117 However, in the 2019 HYPERION trial of patients with coma, after resuscitation from
118 cardiac arrest with nonshockable rhythm, the 33°C hypothermic management group had
119 better 90-day neurological outcomes compared to that of the 37°C normothermia

120 management group.⁹ In addition, two reports on temperature management using the Japanese
121 Association for Acute Medicine Out-of-Hospital Cardiac Arrest (JAAM-OHCA) Registry
122 reported three severity categories (mild, moderate, and severe), that were calculated from
123 variables including the electrocardiogram (ECG), witnessed arrest, hypoperfusion time, blood
124 gas (pH and lactate), and the Glasgow Coma Scale score and averred that hypothermic
125 management was effective in the moderate, but not mild and severe, categories.¹⁰ However,
126 another report of patients on ECMO from the JAAM-OHCA Registry, showed that
127 hypothermic management was ineffective.¹¹ Previous analyses by disease severity have been
128 performed; however, no disease-specific analyses have been conducted.¹⁰ These conflicting
129 results have hindered the establishment of a uniform standard temperature setting for
130 temperature control.¹²

131 This study was conducted with an aim to compare the outcome of hypothermic and
132 normothermic cardiopulmonary resuscitation management under ECMO; thus, contributing
133 to the development of methods for the management of body temperature after a cardiac
134 arrest.

135

136 **Methods**

137 *Study design*

138 This study involved a secondary analysis of data that were provided by the SAVE-J II Study
139 Group – a retrospective, multicenter registry study with 36 participating centers in Japan, that
140 was based on enrolment in the University Hospital Medical Information Network Clinical
141 Trials Registry and the Japanese clinical trial registry (registration number:
142 UMIN000036490).¹³

143 The SAVE-J II Study included adult patients (age ≥ 18 years) who were transported directly
144 to the emergency department of a participating facility for treatment of out-of-hospital

145 cardiac arrest (OHCA) and underwent ECPR in the resuscitation room before return of
146 spontaneous circulation (ROSC) between January 1, 2013, and December 31, 2018.
147 Undergoing ECMO in addition to conventional CPR was defined as ECPR. Patients who
148 underwent ECMO after ROSC, patients transferred from other hospitals, those with
149 exogenous diseases, acute aortic dissection/aneurysm other than cardiogenic causes, and
150 primary brain injury were excluded. Cases in which the cause of cardiopulmonary arrest
151 could not be determined to be cardiogenic at the time of the visit, but was presumed to be
152 cardiogenic, were not excluded in order to consider the indication for ECPR. Moreover,
153 patients who declined to participate by proxy, such as family members, were excluded. Of the
154 1,646 patients who were enrolled in the SAVE-J II Study, those who died before ICU
155 admission and were ineligible for temperature control (165 patients), whose temperature
156 control information was unknown (608 patients), and whose target body temperature was not
157 in the target temperature range (32.0–36.5°C; n=7) were excluded. Furthermore, we excluded
158 patients with unknown cerebral performance categories (CPC), age, sex, witnesses, bystander
159 CPR, electrocardiogram (ECG), low flow time, and diagnosis (86 patients), which were the
160 variables used in the analysis (Fig. 1).

161

162 ***Data collection***

163 Data were provided by the SAVE-J II Study and included information on age, sex, witnesses,
164 bystander CPR, place of occurrence, ECG at scene and on arrival at the hospital, use of
165 adrenaline and defibrillation, prehospital airway management, heart rate before starting
166 ECMO, treatment-related factors, time course, cause of cardiac arrest, ROSC after hospital
167 arrival, ECMO management information (which included temperature settings), duration of
168 maintenance, and cooling method (use of heat exchangers). Details of the hospital and ICU
169 length of stay, in-hospital mortality, and neurologic outcome (CPC) were also collected. The

170 target temperature was defined as the ECMO set temperature; however, if the temperature
171 setting was changed during ECMO management, the last set temperature was used as the
172 target temperature. ROSC was defined as pulse confirmation that lasted for at least 1 minute.
173 The estimated low-flow time was defined as the time from cardiac arrest to ECMO
174 establishment, if the location of cardiac arrest was an ambulance, or as the time from calling
175 an ambulance to ECMO establishment, if the location of cardiac arrest was a non-ambulance
176 location. Causes of cardiac arrest were categorized as acute coronary syndrome, arrhythmia,
177 myopathy, myocarditis, other cardiac causes, pulmonary embolism, and other non-cardiac
178 causes.

179

180 ***Endpoints***

181 The primary endpoint was survival at 28 days. The secondary endpoint was the neurological
182 outcome at 28 days, as assessed by the CPC (5-point Glasgow-Pittsburgh Cerebral
183 Performance Categories): CPC1: able to work, CPC2: able to perform daily activities without
184 assistance, CPC3: conscious but needs assistance in daily activities, CPC4: coma, and CPC5:
185 death. In this study, CPC1–4 was defined as survival and CPC1–2 was defined as good
186 neurological outcome for analysis.¹⁴

187

188 ***Variables***

189 The target body temperature during ECPR was the main independent study variable and was
190 defined as the final temperature setting of ECMO (the temperature setting of ECMO is
191 defined as the "target temperature" in 0.5°C increments). The target body temperature was
192 divided into 32.0–34.5°C (32–34°C group) and 35.0–36.5°C (35–36°C group) to enable an
193 intergroup comparison. Besides this, each covariate was categorized as follows. Age was
194 categorized into 64 years or younger and 65 years or older; ECG was categorized into 3

195 categories, VF and Pulseless VT, Asystole, and pulseless electrical activity (PEA) ; low
196 flow time, defined as the time from the start of chest compressions to the point before ECMO
197 induction, was categorized into 60 minutes or less and 61 minutes or more; the cause of
198 cardiac arrest was categorized as acute coronary syndrome (ACS), cardiogenic except ACS
199 (arrhythmia, myopathy, myocarditis, and other cardiac causes), and non-cardiogenic
200 (pulmonary embolism and other non-cardiac causes). Patients with serious diseases other than
201 exogenous and cardiogenic illnesses (such as acute aortic dissection/aneurysm, primary brain
202 damage, etc.) were excluded from the SAVE-J II Study.

203

204 ***Analysis***

205 With the primary and secondary endpoints as each dependent variable and the target
206 temperature, sex, age, witnessed arrest, bystander CPR, ECG, low flow time, and causative
207 disease as categorical covariates, a multivariate logistic analysis was performed as the main
208 analysis of this study to calculate the adjusted odd ratio (aOR) and 95% confidence intervals
209 (CIs) for each variable. In addition, a model with an interaction term was created by
210 assuming that the association between the target temperature and outcome was influenced by
211 the ECG waveform and causative disease, and that there was an interaction.^{4,5,7-9,15} If there
212 was a significant interaction, further secondary analysis was performed after stratification by
213 that factor.

214

215 ***Sample size***

216 As this study constitutes a multivariate logistic analysis with 7 factors as covariates in the
217 main and secondary analyses, we determined that a sample size of at least 10 cases per factor,
218 for a total of 70 cases, was necessary.

219

220 ***Ethics***

221 The SAVE-J II Study was approved by the institutional review board of Kagawa University
222 (approval number: 2018-110). For all participating centers, the requirement for patient
223 consent was waived because of the retrospective nature of the study. The study was approved
224 by the Teikyo University School of Medicine Research Ethics Committee (approval number:
225 23-005).

226

227 **Results**

228 ***Description of participants***

229 In this study, a total of 949 patients were included, which comprised 541 participants in the
230 32–34°C group and 408 participants in the 35–36°C group. The percentages of good
231 neurological outcome and survival were 19% and 41%, respectively, for the 32–34°C and 35–
232 36°C groups, compared to 15% and 27% for the 35–36°C group. . (Table 1)

233 In both groups, 60–70% of participants were 64 years old or younger and
234 approximately 85% were male. Moreover, there were 80% witnessed arrests and
235 approximately 60% received bystander CPR. Analysis of the ECGs revealed that 70–75%
236 showed VF and pulseless VT, which are shock-adapted. Target body temperatures of 34.0°C
237 for 32–34°C and 36.0°C for 35–36°C were attained in greater than 80% of the cohort. In each
238 group, heat exchangers were used in approximately 80% of cases, with similar deviations of
239 more than 1°C in approximately 10%, and a small number of equipment problems in less than
240 3% of cases. In both groups, ACS was the causative disease in approximately 65%,
241 cardiogenic other than ACS in just under 30%, and noncardiogenic in 5–8% of cases. (Table
242 1)

243

244 ***Main analysis***

245 The aOR for good neurological outcome at 32–34°C versus 35–36°C at target body
246 temperature was 1.2 (95% CI: 0.8–1.7), and the aOR for survival was 1.7 (95% CI: 1.3–2.3).
247 Good neurological outcome was associated with female sex, bystander CPR, and ECG (VF
248 and Pulseless VT). Survival was associated with target body temperature (32–34°C),
249 witnessed arrest, ECG (VF and Pulseless VT), and low flow time (<60 minutes). (Table 2)

250 Of the interaction terms between target temperature, ECG, and causative disease, the
251 only significant interaction with target temperature was identified as non-ACS cardiogenic
252 cases for ACS in causative disease for good neurological outcome (aOR [95% CI] 2.8 [1.2–
253 6.6]) and for survival (aOR [95% CI] 2.8 [1.4–5.5]). (Table 2)

254

255 **Secondary Analysis**

256 Based on the results of interaction, the 949 participants were stratified into two groups of 616
257 ACS and 269 non-ACS cardiogenic cases for the analysis; in the ACS cases, there was no
258 intragroup difference in the proportion of patients with a favorable outcome. In the group of
259 non-ACS cardiogenic cases at 35–36°C and 32–34°C, the favorable outcome rates were
260 10.3% and 24.2% and the survival rate was 19.8% and 50.3%, respectively (Table 3).

261 Multivariate analysis in the ACS group showed that temperature control was not associated
262 with either neurological outcome or survival (Table 4). However, in the group with non-ACS
263 cardiogenic cases, the aOR for good neurological outcome and survival at 32–34°C versus
264 35–36°C was 2.9 (95% CI: 1.4–6.0) and 3.9 (95% CI: 2.2–6.9), respectively (Table 5).

265

266 **Conclusions**

267 In the main analysis, although the target body temperature of 32–34°C (hypothermic
268 management) was not a significant factor for better neurological outcome as compared to
269 management at 35–36°C (normothermic control), this was a significant outcome-related

270 factor for survival. On the other hand, when disease was considered, cardiogenicity due to
271 ACS was not a significant factor for either neurological outcome or survival whereas
272 cardiogenicity other than ACS (arrhythmia, myopathy, myocarditis, and other cardiac causes)
273 was a significant factor for both neurological outcome and survival.

274 Traditionally, hypothermic management has been aimed at a cerebroprotective effect.
275 When cerebral blood flow is disrupted by cardiac arrest, anaerobic glycolysis occurs,
276 inducing structural changes in the Na⁺/K⁺ATPase and Ca²⁺-ATPase and triggering glutamate
277 release into the extracellular space, which results in a sustained intracellular Ca²⁺ influx. The
278 increase in intracellular Ca²⁺ concentration leads to lipid peroxide and free radical
279 production, which results in cell death.¹⁶ Hypothermic management likely confers a brain
280 protective effect by decreasing brain metabolism, and suppressing oxygen consumption and
281 glutamate release.¹⁷ However, the cerebroprotective effect alone is insufficient to explain why
282 hypothermic management constitutes a significant prognostic factor for survival. On the other
283 hand, myocardial injury progresses due to a decrease in the myocardial ATP content,
284 secondary to the progression of anaerobic glycolysis due to the disruption of coronary artery
285 blood flow. This myocardial injury has both reversible and irreversible components, wherein
286 the former comprises stunned myocardium and the latter includes cell death. To improve the
287 outcome after cardiac arrest, it is important to improve the rate of recovery of cardiac
288 function from the state of myocardial stunning.¹⁸ Experimental studies examining the effects
289 of ischemia time and ischemia temperature on the rate of recovery of cardiac function after
290 ischemia and reperfusion, have shown that the rate of recovery of cardiac function and
291 residual ATP content are not reduced with prolonged ischemia time at low temperature,
292 whereas at room temperature, both the rate of cardiac function recovery and residual ATP
293 content are significantly reduced by prolonged ischemia time.¹⁹ This myocardial protective
294 effect of hypothermic control may be related to the fact that hypothermic control was a

295 significant prognostic factor for survival in the present study.

296 In ACS, cell death is often accompanied by impaired cell membrane damage and
297 deviations in intracellular enzymatic activity. In particular, the ACS patients in this study
298 were already in a state of cardiac arrest, and even if urgent PCI was performed, many of them
299 had myocardial cell death; moreover, mechanical complications such as acute mitral
300 regurgitation due to papillary muscle tear and ventricular septal defect may have been
301 associated with the outcomes and the hypothermic management of myocardial stunting. The
302 impact of improved recovery of cardiac function from the condition may have been limited.
303 However, in myopathy and myocarditis, if the patient survives the acute stage, the disease
304 will spontaneously alleviate and likely ensure a favorable outcome. This is because in
305 myopathy and myocarditis, hypoxia due to pump failure worsens and leads to cardiac arrest,
306 which results in fewer myocardial cells experiencing cell death and more recovery of cardiac
307 function from the state of myocardial stunting. Therefore, in cardiomyopathies other than
308 ACS, hypothermic management may have been a significant factor for both neurological
309 outcome and survival compared to normothermic management.

310 The results of previous studies on TTM after cardiac arrest are not uniform, and the results
311 of this study may appear to contradict the findings of some previous studies. First, the
312 uniqueness of this study is that the analysis was performed with stable circulatory and
313 temperature management by ECMO, and taking into account the underlying disease; by using
314 a heat exchanger in the ECMO circuit at 80%, the deviation of more than 1°C was limited to
315 approximately 10%; therefore, we infer that stable temperature control was achieved. On the
316 other hand, as hypothermic management suppresses circulatory dynamics, many patients in
317 previous studies that did not use ECMO may have suffered cardiac arrest again before
318 recovery from myocardial stunting. The TTM-1 Study, TTM-2 Study, and part of the JAAM-
319 OHCA Registry reported that hypothermia management was not effective,^{6,7,10} while the

320 HYPERION trial and another part of the JAAM-OHCA Registry reported that hypothermia
321 management was effective.^{9,10} The TTM-1 trial included patients with cardiac arrest of
322 presumed cardiac cause, the TTM-2 trial included patients with cardiac arrest of presumed or
323 unknown cause, regardless of initial rhythm,^{7,8} and the HYPERION trial included patients
324 resuscitated from non-shocking rhythm cardiac arrest from any cause and does not consider
325 whether the patient has ACS.⁹ The OHCA Registry report analyzed patients according to
326 whether ECMO was performed and severity of illness, and did not consider causative
327 illness.¹⁰ Therefore, when the discrepancies in these series of reports on the effectiveness of
328 hypothermia management are examined in light of the results of this study, it is presumed that
329 the composition of causative diseases in each report was different, which may have affected
330 the effectiveness of hypothermia management. Regarding the JAAM-OHCA Registry study
331 that focused on patients who underwent TTM with ECMO, it was reported that hypothermic
332 management was not necessary. However, as in other previous studies, whether the causative
333 disease was ACS was not considered. Although this report does not exclude ROSC cases
334 prior to the introduction of ECMO, which was excluded in this study, and as a simple
335 prognostic comparison cannot be made, the neurological outcome (CPC1-2) at 30 days for
336 both the 32–34°C and 35–36°C groups was 15% and the 30-day survival rate was 35%,
337 which is considered to be the same level as the survival and good outcome rates in the ACS
338 of this study.¹¹

339 There are three limitations of this study. The first is that because the criteria for ECMO
340 implementation and the method of temperature management are left to the institutional
341 standards, the inclusion and distribution of patients may be arbitrary in such a way that
342 hypothermic management was implemented for patients who have witnessed bystander CPR,
343 and are expected to have a good outcome. Although this study addresses the variables of
344 witnessed arrest, bystander CPR, age, and low perfusion time, there may be other factors that

345 influence the inclusion of hypothermia management.

346 Second, there is no information on the method of temperature management, such as the
347 time to maintain the target body temperature and the site of temperature measurement.

348 However, we confirmed that more than 80% of the target body temperatures were 34.0°C for
349 hypothermic management and 36.0°C for normothermic management, and that there was no
350 significant difference in maintenance time, use of heat exchangers, or temperature deviation
351 rates between the two groups of hypothermia and normothermia managements. Thus, we can
352 assume that differences in measurement and control methods are small.

353 Third, the degree of myocardial necrosis was not examined quantitatively. The present
354 study assumes that the degree of myocardial necrosis in ACS is high, and the classification of
355 the causative disease can be considered to outline the degree of myocardial necrosis.

356 However, the degree of myocardial necrosis may differ even when inpatients are classified as
357 having the same ACS, and myocardial necrosis may be advanced in other cardiogenic
358 conditions besides ACS that lead to cardiac arrest. Quantitative studies would be possible by
359 measuring myocardial deviation enzymes and other parameters.

360 As described above, although the influence of limitation cannot be completely eliminated
361 in the use of registry data, we judged that we were able to minimize its influence so that it did
362 not detract from the usefulness of the results of this study. However, prospective validation is
363 needed with a clearly defined plan that includes the criteria for the introduction of ECMO,
364 methods of temperature control, and validation of the extent of myocardial necrosis.

365 In temperature management using ECMO after ECPR induction, target body temperature of
366 32–34°C (hypothermic management) was a significant prognostic determinant for survival as
367 compared to that of 35–36°C (normothermic management). In addition, neither management
368 was a significant factor for neurological outcome and survival in cardiogenicity due to ACS,
369 although both were significant factors for good neurological outcome and survival in

370 cardiogenicity other than ACS (arrhythmia, myopathy, myocarditis, and other cardiac causes).

371 Myocardial protection by hypothermic management may have an effect.

372

373 **Acknowledgments**

374 Hirotaka Sawano, M.D., Ph.D. (Osaka Saiseikai Senri Hospital), Yuko Egawa, M.D.,
375 Shunichi Kato, M.D. (Saitama Red Cross Hospital), Naofumi Bunya, M.D., Takehiko Kasai,
376 M.D. (Sapporo Medical University), Shinichi Ijuin, M.D., Shinichi Nakayama, M.D., Ph.D.
377 (Hyogo Emergency Medical Center), Seiya Kanou, M.D. (Teikyo University Hospital), Toru
378 Takiguchi, M.D.(Nippon Medical School), Hiroaki Takada, M.D., Kazushige Inoue, M.D.
379 (National Hospital Organization Disaster Medical Center), Ichiro Takeuchi, M.D., Ph.D.,
380 Hiroshi Honzawa, M.D. (Yokohama City University Medical Center), Makoto Kobayashi,
381 M.D., Ph.D., Tomohiro Hamagami, M.D. (Toyooka Public Hospital), Wataru Takayama,
382 M.D., Yasuhiro Otomo, M.D., Ph.D. (Tokyo Medical and Dental University Hospital of
383 Medicine), Kunihiko Maekawa, M.D. (Hokkaido University Hospital), Takafumi Shimizu,
384 M.D., Satoshi Nara, M.D. (Teine Keijinkai Hospital), Michitaka Nasu, M.D., Kuniko
385 Takahashi, M.D. (Urasoe General Hospital), Yoshihiro Hagiwara, M.D., M.P.H. (Imperial
386 Foundation Saiseikai, Utsunomiya Hospital), Shigeki Kushimoto, M.D., Ph.D. (Tohoku
387 University Graduate School of Medicine), Reo Fukuda, M.D. (Nippon Medical School Tama
388 Nagayama Hospital), Takayuki Ogura, M.D., Ph.D. (Japan Red Cross Maebashi Hospital),
389 Shin-ichiro Shiraishi, M.D. (Aizu Central Hospital), Ryosuke Zushi, M.D. (Osaka Mishima
390 Emergency Critical Care Center), Norio Otani, M.D. (St. Luke's International Hospital),
391 Kazuhiro Watanabe, M.D. (Nihon University Hospital), Takuo Nakagami, M.D.
392 (Omihachiman Community Medical Center), Tomohisa Shoko, M.D., Ph.D. (Tokyo Women's
393 Medical University Medical Center East), Nobuya Kitamura, M.D., Ph.D. (Kimitsu Chuo
394 Hospital), Takayuki Otani, M.D. (Hiroshima City Hiroshima Citizens Hospital), Yoshinori

395 Matsuoka, M.D., Ph.D. (Kobe City Medical Center General Hospital), Makoto Aoki, M.D.,
396 Ph.D. (Gunma University Graduate School of Medicine), Masaaki Sakuraya, M.D., M.P.H.
397 (JA Hiroshima General Hospital Hiroshima), Hideki Arimoto, M.D. (Osaka City General
398 Hospital), Koichiro Homma, M.D., Ph.D. (Keio University School of Medicine), Hiromichi
399 Naito, M.D., Ph.D. (Okayama University Hospital), Shunichiro Nakao, M.D., Ph.D. (Osaka
400 University Graduate School of Medicine), Tomoya Okazaki, M.D., Ph.D. (Kagawa
401 University Hospital), Yoshio Tahara, M.D., Ph.D. (National Cerebral and Cardiovascular
402 Center), Hiroshi Okamoto, M.D, M.P.H. (St. Luke’s International Hospital), Jun Kunikata,
403 M.D., Ph.D., Hideto Yokoi, M.D., Ph.D. (Kagawa University Hospital).

404

405 **Sources of Funding**

406 This work was supported by the Japan Society for the Promotion of Science KAKENHI to
407 JK(JP19K18365) and YK (JP19K09419). The funding organization did not play any role in
408 the study; the views expressed in this paper do not reflect the views of the Ministry.

409

410 **Disclosures**

411 None

412

413

414

415

416

417

418

419

420

421 **References**

422 1 Laussen PC, Guerguerian AM. Establishing and Sustaining an ECPR Program. *Frontiers in*

423 *Pediatrics*. 2018;6:152.

424 2 Sakamoto T, Morimura N, Nagao K, Asai Y, Yokota H, Nara S, Hase M, Tahara Y, Atsumi

425 T, SAVE-J Study Group. Extracorporeal Cardiopulmonary Resuscitation versus Conventional

426 Cardiopulmonary Resuscitation in Adults with Out-of-Hospital Cardiac Arrest: a Prospective

427 Observational Study. *Resuscitation*. 2014;85:762–768.

428 3 Hifumi T, Inoue A, Takiguchi T, Watanabe K, Ogura T, Okazaki T, Ijuin S, Zushi R,

429 Arimoto H, Takada H, et al. Variability of Extracorporeal Cardiopulmonary Resuscitation

430 Practice in Patients With Out-of-Hospital Cardiac Arrest From the Emergency Department to

431 Intensive Care Unit in Japan. *Acute Medicine & Surgery*. 2021;8:e647.

432 4 Hypothermia after Cardiac Arrest Study Group. Mild Therapeutic Hypothermia to Improve

433 the Neurologic Outcome After Cardiac Arrest. *New England Journal of Medicine*.

434 2002;346:549–556.

435 5 Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, Smith K.

436 Treatment of Comatose Survivors of Out-of-Hospital Cardiac Arrest With Induced

437 Hypothermia. *New England Journal of Medicine*. 2002;346:557–563.

438 6 Nolan JP, Hazinski MF, Steen PA, Becker LB. Controversial Topics from the 2005

439 International Consensus Conference on Cardiopulmonary Resuscitation and Emergency

440 Cardiovascular Care Science with Treatment Recommendations. *Resuscitation*. 2005;67:175–

441 179.

442 7 Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, Horn J, Hovdenes J,

443 Kjaergaard J, Kuiper M, et al. Targeted Temperature Management at 33°C Versus 36°C After

444 Cardiac Arrest. *New England Journal of Medicine*. 2013;369:2197–2206.

- 445 8 Dankiewicz J, Cronberg T, Lilja G, Jakobsen JC, Levin H, Ullén S, Rylander C, Wise MP,
446 Oddo M, Cariou A, et al. Hypothermia versus Normothermia after Out-of-Hospital Cardiac
447 Arrest. *New England Journal of Medicine*. 2021;384:2283–2294.
- 448 9 Lascarrou JB, Merdji H, Le Gouge A, Colin G, Grillet G, Girardie P, Coupez E, Dequin PF,
449 Cariou A, Boulain T, et al. Targeted Temperature Management for Cardiac Arrest with
450 Nonshockable Rhythm. *New England Journal of Medicine*. 2019;381:2327–2337.
- 451 10 Nishikimi M, Ogura T, Nishida K, Hayashida K, Emoto R, Matsui S, Matsuda N, Iwami T.
452 Outcome Related to Level of Targeted Temperature Management in Postcardiac Arrest
453 Syndrome of Low, Moderate, and High Severities: A Nationwide Multicenter Prospective
454 Registry. *Critical Care Medicine*. 2021;49:e741–e750.
- 455 11 Watanabe M, Matsuyama T, Miyamoto Y, Kitamura T, Komukai S, Ohta B. The Impact of
456 Different Targeted Temperatures on Out-of-Hospital Cardiac Arrest Outcomes in Patients
457 Receiving Extracorporeal Membrane Oxygenation: A Nationwide Cohort Study. *Critical
458 Care*. 2022;26:380.
- 459 12 Inoue A, Hifumi T, Sakamoto T, Okamoto H, Kunikata J, Yokoi H, Sawano H, Egawa Y,
460 Kato S, Sugiyama K *et al*. Extracorporeal Cardiopulmonary Resuscitation in Adult Patients
461 with Out-of-Hospital Cardiac Arrest: a Retrospective Large Cohort Multicenter Study in
462 Japan. *Critical Care*. 2022;26:129.
- 463 13 Fuernau G, Beck J, Desch S, Eitel I, Jung C, Erbs S, Mangner N, Lurz P, Fengler K, Jobs
464 A *et al*. Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction.
465 *Circulation*. 2019;139:448-457.
- 466 14 Berg KM, Soar J, Andersen LW, Böttiger BW, Cacciola S, Callaway CW, Couper K,
467 Cronberg T, D'Arrigo S, Deakin CD, et al. Adult Advanced Life Support: 2020 International
468 Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science
469 With Treatment Recommendations. *Circulation*. 2020;142:S92–S139.

- 470 15 Balouris SA, Raina KD, Rittenberger JC, Callaway CW, Rogers JC, Holm MB.
471 Development and Validation of the Cerebral Performance Categories-Extended (CPC-E).
472 *Resuscitation*. 2015;94:98-105.
- 473 16 Varon J, Acosta P. Therapeutic Hypothermia: Past, Present, and Future. *Chest*.
474 2008;133:1267–1274.
- 475 17 Alzaga AG, Cerdan M, Varon J. Therapeutic Hypothermia. *Resuscitation*. 2006;70:369–
476 380.
- 477 18 Braunwald E, Kloner RA. The Stunned Myocardium: Prolonged, Postischemic Ventricular
478 Dysfunction. *Circulation*. 1982;66:1146–1149.
- 479 19 Hearse DJ. Cardioplegia. *Postgraduate Medical Journal*. 1983;59;Suppl 2:11–24.
480

481 **Figure Legend**

482 Figure 1. Flowchart depicting participant selection.

483 ICU: intensive care unit, CPC: cerebral performance categories, CPR: cardiopulmonary

484 resuscitation, ECG: electrocardiogram

485 Table 1. Description of the participants' characteristics.

		35-36°C		32-34°C	
		n=408	(%)	n=541	(%)
Good neurological prognosis (CPC1-2)		62	(15.2)	102	(18.9)
Survival (CPC1-4)		111	(27.2)	224	(41.4)
CPC	1	41	(10.0)	82	(15.2)
	2	21	(5.1)	20	(3.7)
	3	15	(3.7)	33	(6.1)
	4	34	(8.3)	89	(16.5)
	5	297	(72.8)	317	(58.6)
Sex					
	Male	349	(85.5)	457	(84.5)
Age (years)					

	-64	244	(59.8)	367	(67.8)
Witnessed arrest		320	(78.4)	438	(81.0)
Bystander CPR		247	(60.5)	312	(57.7)
ECG					
	VF and pulseless VT	282	(69.1)	406	(75.0)
	Asystole	36	(8.8)	26	(4.8)
	PEA	90	(22.1)	109	(20.1)
Low perfusion time (minutes)					
	-60	259	(63.5)	385	(71.2)
Cause of cardiac arrest					
	ACS	270	(66.2)	346	(64.0)
	Cardiogenic except ACS	116	(28.4)	153	(28.3)
	Arrhythmia	69		77	

	Myocarditis	6		9	
	Myopathy	24		42	
	Other cardiac causes	17		25	
	Non-cardiogenic	22	(5.4)	42	(7.8)
	Pulmonary embolism	15		23	
	Other non-cardiac causes	7		19	
Target body temperature (°C)					
	32.0	0	(0.0)	22	(4.1)
	32.5	0	(0.0)	1	(0.2)
	33.0	0	(0.0)	64	(11.8)
	33.5	0	(0.0)	7	(1.3)
	34.0	0	(0.0)	441	(81.5)
	34.5	0	(0.0)	6	(1.1)
	35.0	50	(12.3)	0	(0.0)
	35.5	6	(1.5)	0	(0.0)

36.0	339	(83.1)	0	(0.0)
36.5	13	(3.2)	0	(0.0)
Time to maintain the target body temperature (hours)				
-23	204	(77.3)	427	(84.4)
24-48	47	(17.8)	73	(14.4)
49-	13	(4.9)	6	(1.2)
Unknown	144		35	
Temperature deviation (>1°C)				
None	45	(12.1)	60	(11.4)
None	326	(87.9)	465	(88.6)
Unknown	37		16	
Heat exchangers				
None	296	(78.3)	440	(85.6)
None	82	(21.7)	74	(14.4)
Unknown	30		27	
Equipment trouble				
	5	(1.2)	19	(3.5)

None	400	(98.8)	518	(96.5)
Unknown	3		4	

486

487 CPC: cerebral performance categories, CPR: cardiopulmonary resuscitation, ECG: electrocardiogram, VF: ventricular fibrillation, VT:

488 ventricular tachycardia, PEA: pulseless electrical activity, ACS: acute coronary syndrome

489

490 Table 2. The odds ratio of factors which are likely to influence patient prognoses (ALL)

	Good neurological prognosis (CPC1-2)					Survival (CPC1-4)					
	cOR		aOR		aOR (with Interaction term)	cOR		aOR		aOR (with Interaction term)	
Target body temperature (ref 35-36°C)											
32-34°C	1.2 97	(0.918- 1.882)	1.2 15	(0.849- 1.740)	0.954	(0.599- 1.522)	1.8 91	(1.433- 2.495)	1.7 42	(1.307- 2.322)	1.460 (0.998- 2.137)
Sex (ref female)											
male	0.5 88	(0.384- 0.900)	0.5 26	(0.329- 0.841)	0.547	(0.339- 0.882)	0.7 94	(0.552- 1.144)	0.6 97	(0.467- 1.041)	0.728 (0.483- 1.096)
Age (ref 65-)											
-64	1.3 67	(0.950- 1.969)	1.2 06	(0.22- 1.770)	1.226	(0.929- 2.549)	1.3 97	(1.052- 1.854)	1.2 36	(0.915- 1.670)	1.250 (0.922- 1.695)

Witnessed arrest

1.7	(1.095-	1.5	(0.955-	1.539	(0.929-	1.4	(1.056-	1.5	(1.049-	1.487	(1.023-
71	2.862)	78	2.605)		2.549)	95	2.116)	20	2.202)		2.163)

Bystander CPR

1.9	(1.339-	1.9	(1.297-	1.960	(1.331-	1.1	(0.882-	1.1	(0.864-	1.193	(0.888-
32	2.787)	04	2.795)		2.886)	58	1.520)	56	1.548)		1.602)

ECG (ref VF and pulseless
VT)

Asystole	0.2	(0.097-	0.2	(0.101-	0.266	(0.060-	0.3	(0.186-	0.4	(0.221-	0.476	(0.187-
	72	0.763)	88	0.820)		1.171)	56	0.681)	31	0.840)		1.214)

PEA	0.4	(0.286-	0.3	(0.196-	0.406	(0.179-	0.4	(0.310-	0.4	(0.267-	0.552	(0.301-
	66	0.760)	42	0.596)		0.918)	46	0.641)	00	0.599)		1.011)

Low perfusion time (minutes)
(ref 61-)

-60	1.5	(1.074-	1.4	(0.999-	1.517	(1.018-	1.9	(1.462-	1.8	(1.347-	1.877	(1.370-
	80	2.324)	84	2.206)		2.261)	79	2.679)	40	2.514)		2.571)

Cause of cardiac arrest (ref
ACS)

Cardiogenic except ACS	1.1 09	(0.762- 1.614)	0.9 14	(0.614- 1.360)	0.468	(0.232- 0.945)	1.1 04	(0.820- 1.486)	0.9 66	(0.703- 1.327)	0.505	(0.293- 0.868)
Non-cardiogenic	1.1 49	(0.593- 2.229)	1.4 29	(0.660- 3.094)	1.592	(0.480- 5.397)	0.8 48	(0.487- 1.475)	1.1 29	(0.599- 2.126)	1.277	(0.451- 3.614)

Interaction term with the target
body temperature
ECG (ref VF and pulseless
VT)

Asystole					1.215	(0.149- 9.914)					0.843	(0.220- 3.223)
PEA					0.744	(0.248- 2.230)					0.584	(0.263- 1.299)

Cause of cardiac arrest (ref
ACS)

Cardiogenic except ACS	2.836	(1.216- 6.617)	2.818	(1.441- 5.510)
Non-cardiogenic	0.892	(0.191- 4.174)	0.906	(0.252- 3.264)

491

492 CPC: cerebral performance categories, cOR: crude odds ratio, aOR: adjusted odds ratio, CPR: cardiopulmonary resuscitation, ECG:

493 electrocardiogram, VF: ventricular fibrillation, VT: ventricular tachycardia, PEA: pulseless electrical activity, ACS: acute coronary syndrome

494

495

496

497

498

499

500 Table 3. Description of participant characteristics in the ACS and cardiogenic shock (except ACS) groups.

		AC S				Cardiogenic except ACS			
		35- 36°C n=270 (%)		32- 34°C n=346 (%)		35- 36°C n=116 (%)		32- 34°C n=153 (%)	
Good neurological prognosis (CPC1-2)		45	(16.7)	58	(16.8)	12	(10.3)	37	(24.2)
Survival (CPC1-4)		81	(30.0)	134	(38.7)	23	(19.8)	77	(50.3)
CPC	1	30	(11.1)	44	(12.7)	7	(6.0)	33	(21.6)
	2	15	(5.6)	14	(4.0)	5	(4.3)	4	(2.6)

	3	10	(3.7)	25	(7.2)	3	(2.6)	6	(3.9)
	4	26	(9.6)	51	(14.7)	8	(6.9)	34	(22.2)
	5	189	(70.0)	212	(61.3)	93	(80.2)	78	(49.7)
Sex									
	Male	245	(90.7)	314	(90.8)	96	(82.8)	116	(75.8)
Age, years									
	-64	150	(55.6)	217	(62.7)	81	(69.8)	116	(75.8)
Witnessed arrest		215	(70.0)	271	(78.3)	89	(76.7)	131	(85.6)

Bystander CPR	156	(57.8)	195	(56.4)	75	(64.7)	87	(56.9)
---------------	-----	--------	-----	--------	----	--------	----	--------

ECG

VF and pulseless VT	192	(71.1)	269	(77.7)	86	(74.1)	128	(83.7)
Asystole	21	(7.8)	15	(4.3)	11	(9.5)	6	(3.9)
PEA	57	(21.1)	62	(17.9)	19	(16.4)	19	(12.4)

Low perfusion time (minutes) (ref 61-)

-60	169	(62.6)	252	(72.8)	77	(66.4)	107	(69.9)
-----	-----	--------	-----	--------	----	--------	-----	--------

Target body temperature (°C)

32.0	0	(0.0)	18	(5.2)	0	(0.0)	2	(1.3)
32.5	0	(0.0)	1	(0.3)	0	(0.0)	0	(0.0)
33.0	0	(0.0)	44	(12.7)	0	(0.0)	18	(11.8)
33.5	0	(0.0)	3	(0.9)	0	(0.0)	4	(2.6)
34.0	0	(0.0)	274	(79.2)	0	(0.0)	129	(84.3)
34.5	0	(0.0)	6	(1.7)	0	(0.0)	0	(0.0)
35.0	35	(13.0)	0	(0.0)	14	(12.1)	0	(0.0)
35.5	4	(1.5)	0	(0.0)	2	(1.7)	0	(0.0)
36.0	221	(81.9)	0	(0.0)	88	(84.5)	0	(0.0)
36.5	10	(3.7)	0	(0.0)	2	(1.7)	0	(0.0)

Time to maintain the target body
temperature (hours)

-23	132	(77.2)	281	(85.7)	60	(76.9)	114	(80.9)
24-48	31	(18.1)	44	(13.4)	15	(19.2)	24	(17.0)
49-	8	(4.7)	3	(0.9)	3	(3.8)	3	(2.1)
Unknown	99		18		38		12	
PCI	217	(81.0)	282	(81.7)				
None	51	(19.0)	63	(18.3)				
Unknown	2		1					
Temperature deviation (>1°C)	28	(11.4)	39	(11.5)	17	(16.5)	15	(10.3)

	None	218	(88.6)	300	(88.5)	86	(83.5)	131	(89.7)
	Unknown	19		16		13			
Heat exchangers		195	(77.7)	280	(84.8)	82	(78.1)	126	(88.1)
	None	56	(22.3)	50	(15.2)	23	(21.9)	17	(11.9)
	Unknown	19		16		11		10	
Equipment trouble		4	(1.5)	11	(3.2)	1	(0.9)	7	(4.6)
	None	264	(98.5)	334	(96.8)	114	(99.1)	144	(95.4)
	Unknown	2		1		1		2	

501

502 ACS: acute coronary syndrome, CPC: cerebral performance categories, cOR: crude odds ratio, aOR: adjusted odds ratio, CPR: cardiopulmonary

503 resuscitation, ECG: electrocardiogram, VF: ventricular fibrillation, VT: ventricular tachycardia, PEA: pulseless electrical activity

504 Table 4. Odds ratio of factors that are likely to influence patient prognoses (ACS).

	Good neurological prognosis (CPC1-2)				Survival (CPC1-4)			
	cOR		aOR		cOR		aOR	
Target body temperature (ref 35-36°C)								
32-34°C	1.00 7	(0.657-1.543)	0.907	(0.581-1.415)	1.00 7	(0.657-1.543)	1.33 8	(0.940-1.905)
Sex (ref female)								
Male	0.58 2	(0.305-1.108)	0.453	(0.228-0.899)	0.58 2	(0.305-1.108)	0.51 5	(0.286-0.925)
Age (ref 65-)								
-64	1.46 4	(0.816-2.503)	1.293	(0.809-2.066)	1.45 4	(0.937-2.288)	1.16 7	(0.814-1.675)
Witnessed arrest								

	1.42 9	(0.816-2.503)	1.350	(0.749- 2.435)	1.42 9	(0.816- 2.503)	1.44 0	(0.922- 2.251)
Bystander CPR								
	1.94 8	(1.235-3.072)	1.967	(1.223- 3.162)	1.94 8	(1.235- 3.072)	1.29 1	(0.902- 1.847)
ECG (ref VF and pulseless VT)								
Asystole	0.11 5	(1.074-2.324)	0.116	(0.016- 0.870)	0.11 5	(0.015- 0.847)	0.50 2	(0.219- 1.146)
PEA	0.36 8	(0.185-0.731)	0.317	(0.155- 0.645)	0.36 8	(0.185- 0.731)	0.34 5	(0.207- 0.573)
Low perfusion time (minutes) (ref 61-)								
-60	1.58 0	(1.704-2.324)	1.608	(0.968- 2.670)	1.58 0	(1.074- 2.324)	2.04 8	(1.381- 3.037)

505

506 ACS: acute coronary syndrome, CPC: cerebral performance categories, cOR: crude odds ratio, aOR: adjusted odds ratio, CPR: cardiopulmonary

507 resuscitation, ECG: electrocardiogram, VF: ventricular fibrillation, VT: ventricular tachycardia, PEA: pulseless electrical activity

508 Table 5. Odds ratio of factors that are likely to influence patient prognoses (cardiogenic shock, except ACS).

	Good neurological prognosis (CPC1-2)				Survival (CPC1-4)			
	cOR		aOR		cOR		aOR	
Target body temperature (ref 35-36°C)								
32-34°C	2.76 4	(1.369-5.583)	2.870	(1.362-6.049)	4.09 7	(2.350-7.141)	3.86 7	(2.161-6.919)
Sex (ref female)								
male	0.53 5	(0.267-1.071)	0.558	(0.264-1.179)	0.84 3	(0.463-1.534)	0.92 3	(0.479-1.776)
Age (ref 65-)								
-64	1.32 5	(0.637-2.759)	1.194	(0.537-2.655)	1.49 0	(0.837-2.653)	1.35 8	(0.717-2.569)
Witnessed arrest								

	1.42	(0.816-2.503)	2.829	(0.806-9.932)	1.42	(0.816-2.503)	1.87	(0.858-4.082)
	9				9		2	
Bystander CPR								
	2.67	(1.299-5.506)	2.890	(1.327-6.925)	1.05	(0.635-1.747)	1.16	(0.652-2.070)
	4				3		2	
ECG (ref VF and pulseless VT)								
Asystole	0.51	(0.114-2.337)	0.665	(0.138-3.199)	0.30	(0.084-1.078)	0.42	(0.109-1.615)
	5				1		0	
PEA	0.33	(0.097-1.127)	0.283	(0.080-1.008)	0.37	(0.164-3.714)	0.39	(0.164-0.957)
	1				5		7	
Low perfusion time (minutes) (ref 61-)								
-60	1.53	(0.754-3.111)	1.487	(0.698-3.169)	2.10	(1.196-3.714)	2.04	(1.114-3.767)
	1				7		9	

509

510 ACS: acute coronary syndrome, CPC: cerebral performance categories, cOR: crude odds ratio, aOR: adjusted odds ratio, CPR: cardiopulmonary

511 resuscitation, ECG: electrocardiogram, VF: ventricular fibrillation, VT: ventricular tachycardia, PEA: pulseless electrical activity

